Disc Medicine Inc. (IRON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Disc Medicine Inc. (IRON) has a cash flow conversion efficiency ratio of -0.090x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.24 Million) by net assets ($688.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Disc Medicine Inc.'s balance sheet to measure how much of total assets are equity-financed.
Disc Medicine Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Disc Medicine Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Disc Medicine Inc. total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Disc Medicine Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Disc Medicine Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sany Heavy Energy Co. Ltd. A
SHG:688349
|
N/A |
|
Denison Mines Corp
TO:DML
|
-0.023x |
|
Eurazeo
PA:RF
|
0.012x |
|
Taseko Mines Ltd
TO:TKO
|
0.113x |
|
YAMAHA CORP.SP.ADR/1 O.N.
F:YHAA
|
N/A |
|
XL Axiata Tbk PT
JK:EXCL
|
0.144x |
|
Workiva Inc
NYSE:WK
|
-2.099x |
|
Autel Intelligent Technology Corp Ltd
SHG:688208
|
0.008x |
Annual Cash Flow Conversion Efficiency for Disc Medicine Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Disc Medicine Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see IRON stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $739.83 Million | $-180.39 Million | -0.244x | -15.16% |
| 2024-12-31 | $443.59 Million | $-93.93 Million | -0.212x | +0.52% |
| 2023-12-31 | $345.12 Million | $-73.46 Million | -0.213x | +11.03% |
| 2022-12-31 | $176.60 Million | $-42.25 Million | -0.239x | -155.79% |
| 2021-12-31 | $-64.20 Million | $-27.53 Million | 0.429x | -71.34% |
| 2020-12-31 | $-21.86 Million | $-32.71 Million | 1.496x | -- |
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more